GC2, in Brazil and InKemia, expand their collaboration agreement by the incorporation of a partnership with Recerca Clínica in order to offer to the pharmaceutical industry a broader spectrum of clinical trials services in Europe, Brazil and Latin America

The Brazilian company GC2 - Gestão do Conhecimento Científico SA, a central laboratory for pre-clinical and clinical research based in São Paulo, and InKemia Brasil, a subsidiary of the European multinational InKemia IUCT Group, dedicated to the generation of high value technological knowledge to support the life sciences industries, extend their partnership for the area of clinical research, incorporating to their agreement the company Recerca Clínica, a clinical contract research organization based in Barcelona, Spain.

The original agreement focused on providing its customers with a complete service for all development stages (new products, manufacture and import of medicines and consulting services) has now been extended to cover pre-clinical and clinical development through the collaboration with Recerca Clínica, an InKemia IUCT Group company.

Recerca Clínica is a contract research organization (CRO) that supports Spanish pharmaceutical companies, biotechnology, medical devices, other CROs, international scientific societies, public institutions and other research centers for planning, designing, and implementing clinical trials, marketing studies, and post-approval trials in various development phases (phases I-IV).

GC2 is a Brazilian central laboratory for clinical and preclinical research, covering all stages from technical feasibility analysis, development planning, up until the execution of clinical and pre-clinical phases focusing on laboratory aspects.

Thus, the collaboration between GC2 and Recerca Clínica offers the European, Brazilian and all Latin America pharmaceutical industries the possibility of clinical studies that include:

  • Laboratory services and centralized image reading;
  • Collaboration in clinical studies with other CROs;
  • Data management services to conduct clinical studies.

With the extent of this collaboration between GC2 and InKemia through Recerca Clínica, full-spectrum service research and without borders is established, allowing pharmaceutical companies to conduct clinical trials for the development of new drugs either in European Union countries, Brazil or in Latin America.

For the CEO of GC2 SA, Dr. Carlos Kiffer, the incorporation of Recerca Clínica "is aligned to the concept of open innovation and to our strategy of operating with a flexible business model that meets the global market demand while maintaining high quality and technical rigor." For Kiffer "the partnership, in addition to completing the portfolio of both companies, will open doors bilaterally in Brazil and in Europe for the pharmaceutical companies to extend their development programs." The CEO of Recerca Clínica, Jordi Roma says: "In global society, I can only understand the business growth based on knowledge sharing of each of the involved parties; ‘share to compete’ for me is the best motto. With this agreement we want to add and provide our customers with the security of being in more markets with the best quality." Óscar Miranda, CEO of InKemia Brazil concludes that "the inclusion of Recerca Clínica with GC2 shows the strategic vision of InKemia which aims to generate knowledge that will become scientific and technical value through a synergistic network of life science companies that operate in the global market. In the end we want our customers to gain efficiency and competitiveness, so that they can offer better products and services.”

The Carbazymes project holds the Mid-Term meeting


The pioneering biotechnology project CarbaZymes, funded with € 8,2 million by the EU’s Horizon 2020 Research and Innovation Programme, held its mid-term review meeting in Brussels in the Mondrian building (CDMA), which houses the Directorate General for Research & Innovation, on 9th September 2016.

Led by the coordinator, Professor W.-D. Fessner from the Technische Universität Darmstadt, PIs, researchers and managers of 7 universities, 6 SMEs and 1 large company met with the Project Officer Dr A. Fuentes and external reviewer Dr E. Atanes. The consortium presented its cutting-edge advances of the project so far, which lie in the area of asymmetric C-C bond formation to obtain high value APIs and essential bulk compounds for industry, starting from potentially sustainable, low priced precursors, by applying novel, engineered biocatalysts.

The CarbaZymes Project, with a collective scientific experience of more than 150 years(!) in biocatalysis, aims to revolutionize certain production methods in the chemical industry and then scale them up to demonstration level. After securing IP, these will be ready to be taken up by the relevant industries. The processes of interest to the CarbaZymes platform aspire to be more efficient and more eco-friendly versions of some widely applied conventional organic chemical syntheses, with the aim to replace potential hazards for the benefit of human health and positively impact the future quality of life for European citizens.

The review meeting was highly successful and the CarbaZymes consortium was encouraged to further pursue novel and emerging spin-off developments along with the main goals of the project.

Note to interested parties:
For more information or interviews, please contact the project manager: A. Theodoridou
e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.
Tel: +49-6151-1623646

Inkemia IUCT boosts its entrepreneurship activity

On May 12, Inkemia IUCT group held the first meeting of companies within the IUCT emprèn environment at its facilities in Mollet del Vallès. 25 people attended the meeting on behalf of 9 companies, including IUCT Inkemia itself. Activities and projects of each of them were presented during the meeting, finishing with a very positive evaluation by participants.

Inkemia IUCT group entrepreneurship activity started in 2011. Up to now, 8 start-up companies with activities in the field of life sciences, have benefited from Inkemia IUCT support. Among those companies are Plasmia, Vytrus, Mind the Byte, Leanbio, Pharmamel, Myogem, BCN Biosciences and Recerca Clínica.

With the organization of this Congress, which will be held on an annual basis, Inkemia IUCT group has taken a step forward in its support to entrepreneurship promoting not only mutual understanding, cooperation and partnership between companies, but also the consolidation and growth of the group.


IUCT has been authorized as importer for human, veterinary and investigational medicinal products

IUCT has been authorized as importer for human, veterinary and investigational medicinal products

For medicinal products manufactured outside the EU, importation and certification are the final stages of manufacturing which precede the transfer to saleable stock of the batch. Therefore being an importer for a medicinal product means being in charge of re-testing, certifying and releasing each batch according to Annex 16 EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary.

IUCT, a company belonging to Inkemia IUCT group, has extended its manufacturer’s authorization nº 4155E (MIA 1106) and has been accredited by the Spanish Agency of Medicines and Medical Devices (AEMPS) as importer on April 1, 2016.

As a consequence, IUCT widens its range of services by adding quality control, batch certification and release in Europe of pharmaceutical products manufactured in third countries.

Additionally, in an effort to provide a global service, IUCT also facilitates other aspects related to the import and marketing of pharmaceutical products in the European Union. Within the range of services IUCT offers you can find management of marketing authorizations in the European countries of your interest, support in getting GMP certification of the manufacturer's facilities, transport & customs and pharmacovigilance services, among others.


Development of the food supplement MYO-DM and its application in Myotonic Type 1 Dystrophy

On the occasion of Rare Disease Day celebrated on February 28th, IUCT, knowledge division of the mother SME company InKemia IUCT group, has been invited to present the results of its work, during the "Open day about Research in Myotonic Dystrophy" that was held in Valencia (Spain), organized by the University of Valencia, in particular by the Translational Genomic Department led by Dr. Ruben Artero.

The event was a great opportunity to put together researchers, doctors, students, patients and patients' Associations in order to show the research and progress made in Myotonic Distrophy, in Spain, during the past years.

IUCT has been invited to talk about all the job and research that has been done, most of it in strict collaboration with Translational Genomic Department of University of Valencia, and to show the results obtained until the date in Myotonic Dystrophy. The formulation developed by IUCT has proved to increase the level of MBNL protein, one of the main involved in the pathogenesis mechanisms of the disease, showing a sensible reduction of the severity of symptoms, both in vitro (patients fibroblasts) and in vivo (Drosophila model).

In order to keep working on the development and commercialization of these results, IUCT licensed out everything to Myogem Health Company, spin-off of Inkemia IUCT Group, furthermore during the speech Myogem officially presented its first product, MYO-DM, a food supplement based on natural extracts whose composition has been defined from the results previously obtained by IUCT.





  •   info@inkemia.com
  •  +34 93 579 34 32
  •  +34 93 570 57 45
  •  C\ Àlvarez de Castro, 63, 08100
    Mollet del Vallès (Barcelona)